Heita Ozawa1, Kenjiro Kotake2, Miki Hosaka2, Akira Hirata2, Yusuke Nakagawa2, Shin Fujita2, Kenichi Sugihara3. 1. Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan. heiozawa@tochigi-cc.jp. 2. Department of Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan. 3. Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Abstract
PURPOSE: This study aimed to clarify the significance of preoperative serum carcinoembryonic antigen (CEA) on disease-free survival (DFS) in colon cancer and propose a new prognostic grouping system. METHODS: A multiinstitutional retrospective cohort of 7296 colon cancer patients who underwent R0 surgery between 1997 and 2006 was analyzed. We stratified preoperative serum CEA values into three categories (C-stages): C0 (normal CEA), C1A (up to double the cutoff value), and C1B (more than double the cutoff value) and stratified each TNM stage by C-stage. Multivariate analyses using Cox regression models were used to analyze the significance of C-stage on 5-year DFS. RESULTS: CEA level was an independent factor affecting DFS; the 5-year DFS of patients with C0 and C1, as well as those with C1A and C1B, differed significantly (C0 84.6%, C1 69.8%, C1A 72.7%, and C1B 66.4%, P < 0.0001). Additionally, the DFS of pStages IIC and C1B was significantly lower than of pStages IIIA and C0 (65.8 vs. 87.7%, respectively; hazard ratio 3.44, 95% confidence interval 1.97-5.88, P < 0.0001). Moreover, the 5-year DFS of pStages IIIA and C0 or C1A did not differ significantly from pStages I and C1A (87.7 vs. 87.7%, P = 0.90 and 86.4 vs. 87.7%, P = 0.78, respectively). CONCLUSIONS: pStage IIC and C1B disease should be considered candidates for intensive adjuvant chemotherapy. Conversely, pStages IIIA and C0 or C1A could be exempted from adjuvant chemotherapy. Incorporating C-stage into the current TNM staging system may facilitate decision making regarding the use of adjuvant chemotherapy in colon cancer patients.
PURPOSE: This study aimed to clarify the significance of preoperative serum carcinoembryonic antigen (CEA) on disease-free survival (DFS) in colon cancer and propose a new prognostic grouping system. METHODS: A multiinstitutional retrospective cohort of 7296 colon cancerpatients who underwent R0 surgery between 1997 and 2006 was analyzed. We stratified preoperative serum CEA values into three categories (C-stages): C0 (normal CEA), C1A (up to double the cutoff value), and C1B (more than double the cutoff value) and stratified each TNM stage by C-stage. Multivariate analyses using Cox regression models were used to analyze the significance of C-stage on 5-year DFS. RESULTS:CEA level was an independent factor affecting DFS; the 5-year DFS of patients with C0 and C1, as well as those with C1A and C1B, differed significantly (C0 84.6%, C1 69.8%, C1A 72.7%, and C1B 66.4%, P < 0.0001). Additionally, the DFS of pStages IIC and C1B was significantly lower than of pStages IIIA and C0 (65.8 vs. 87.7%, respectively; hazard ratio 3.44, 95% confidence interval 1.97-5.88, P < 0.0001). Moreover, the 5-year DFS of pStages IIIA and C0 or C1A did not differ significantly from pStages I and C1A (87.7 vs. 87.7%, P = 0.90 and 86.4 vs. 87.7%, P = 0.78, respectively). CONCLUSIONS: pStage IIC and C1B disease should be considered candidates for intensive adjuvant chemotherapy. Conversely, pStages IIIA and C0 or C1A could be exempted from adjuvant chemotherapy. Incorporating C-stage into the current TNM staging system may facilitate decision making regarding the use of adjuvant chemotherapy in colon cancerpatients.
Authors: Chang Gon Kim; Joong Bae Ahn; Minkyu Jung; Seung Hoon Beom; Su Jin Heo; Jee Hung Kim; Young Jin Kim; Nam Kyu Kim; Byung Soh Min; Woong Sub Koom; Hoguen Kim; Yun Ho Roh; Bo Gyoung Ma; Sang Joon Shin Journal: Ann Surg Oncol Date: 2016-10-03 Impact factor: 5.344
Authors: G I Meling; T O Rognum; O P Clausen; O Børmer; O C Lunde; E Schlichting; O P Grüner; J Hognestad; E Trondsen; O Havig Journal: Scand J Gastroenterol Date: 1992-12 Impact factor: 2.423
Authors: Chan Wook Kim; Yong Sik Yoon; In Ja Park; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim Journal: Ann Surg Oncol Date: 2013-06-13 Impact factor: 5.344
Authors: M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan Journal: Eur J Cancer Date: 2007-05-18 Impact factor: 9.162
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Jian Lv; Yuan Yuan Liu; Yi Tao Jia; Jing Li He; Guang Yao Dai; Peng Guo; Zhao Long Zhao; Yan Ni Zhang; Zhong Xin Li Journal: World J Surg Oncol Date: 2021-12-02 Impact factor: 2.754
Authors: Julia Bergheim; Alexander Semaan; Heidrun Gevensleben; Susanne Groening; Andreas Knoblich; Jörn Dietrich; Julia Weber; Jörg C Kalff; Friedrich Bootz; Glen Kristiansen; Dimo Dietrich Journal: Br J Cancer Date: 2018-04-03 Impact factor: 7.640